CG Oncology - Raised $294M Funding from 17 investors - Tracxn

CG Oncology has raised a total funding of $294M over 4 rounds from 17 investors. Investors include Foresite Capital, RA Capital Management and 15 others. Their latest funding round …

CouponFollow Extension

$294
OFF

CG Oncology - Raised $294M Funding From 17 Investors - Tracxn

2 days from now

CG Oncology has raised a total funding of $294M over 4 rounds from 17 investors. Investors include Foresite Capital, RA Capital Management and 15 others. Their latest funding round …

tracxn.com

$294
OFF

CG Oncology - Company Profile - Tracxn

2 days from now

Oct 11, 2024 · CG Oncology - Developer of immunotherapeutic agents for treating cancer. Public Company. Raised a total funding of $294M over 4 rounds from 17 investors. CG Oncology has …

tracxn.com

$306
OFF

UPDATE 2-Drug Developer CG Oncology Targets Up To $306 Mln …

2 days from now

Jan 23, 2024 · Cancer drug developer CG Oncology said on Tuesday it was aiming to raise up to $306 million in its upsized initial public offering in New York, underscoring the resurgent …

yahoo.com

$380
OFF

CG Oncology Prices Larger-than-expected $380M IPO In Hopeful …

2 days from now

Jan 24, 2024 · Cancer drug developer CG Oncology has raised $380 million in an initial public offering than was larger than it expected, a positive sign for a sector that’s struggled to …

biopharmadive.com

$180
OFF

CG Oncology Lines Up $180m IPO And A $1bn Valuation

2 days from now

Jan 19, 2024 · The biotech is pitching at around $17 per share with the offer, with the total raised potentially reaching $209 million if the underwriters of the listing take up an over-allotment …

pharmaphorum.com

$380
OFF

CG Oncology Is First Biotech IPO Of 2024, Raising $380m

2 days from now

Jan 25, 2024 · CG Oncology completes the first biotech IPO of 2024, ... -based company was expecting to raise around $200 million from an offer of less than 12 million shares priced at …

pharmaphorum.com

$120000000
OFF

Series E - CG Oncology - 2022-11-15 - Crunchbase Funding …

2 days from now

Nov 15, 2022 · CG Oncology raised $120000000 on 2022-11-15 in Series E. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. ... Edit Overview Section. Organization Name . …

crunchbase.com

$209
OFF

CG Oncology Aims For $209M IPO, As More Biotechs Eye Nasdaq

2 days from now

Jan 18, 2024 · CG Oncology is hoping to raise $209 million from its upcoming IPO, blazing a trail to the public markets that seems to be enticing more biotechs in the first month of the year.

fiercebiotech.com

$47
OFF

CG Oncology Closes $47M Series D Funding - Vcnewsdaily.com

2 days from now

CG Oncology, a clinical-stage biopharmaceutical company focused on the development of novel oncolytic immunotherapies, announced the closing of a $47 million Series D preferred stock …

vcnewsdaily.com

$20
OFF

Clovis Oncology - Raised $20M Funding From 13 Investors - Tracxn

2 days from now

Nov 5, 2024 · Clovis Oncology has raised a total funding of $20M over 6 rounds from 13 investors. Investors include Aisling Capital, Frazier Healthcare Partners and 11 others. Their …

tracxn.com

$47
OFF

CG Oncology Closes $47 Million Series D Financing | CG Oncology

2 days from now

IRVINE, Calif., December 10, 2020 – CG Oncology, Inc., a clinical-stage biopharmaceutical company focused on the development of novel oncolytic immunotherapies, today announced …

cgoncology.com

$380
OFF

Cullinan Oncology - Raised $380M Funding From 19 Investors

2 days from now

Nov 8, 2024 · Cullinan Oncology has raised a total funding of $380M over 3 rounds from 19 investors. Investors include Venrock, Foresite Capital and 17 others. Their latest funding round …

tracxn.com

$47
OFF

CG Oncology Closes $47 Million Series D Financing

2 days from now

IRVINE, Calif., December 10, 2020 – CG Oncology, Inc., a clinical-stage biopharmaceutical company focused on the development of novel oncolytic immunotherapies, today announced …

cgoncology.com

FAQs about CG Oncology - Raised $294M Funding from 17 investors - Tracxn Coupon?

Will CG oncology raise $306 million?

Jan 23 (Reuters) - Cancer drug developer CG Oncology said on Tuesday it was aiming to raise up to $306 million in its U.S. initial public offering, higher than it had previously expected. ...

Why did CG Oncology raise $380 million in its IPO?

Cancer drug developer CG Oncology has raised $380 million in an initial public offering. The company sold 20 million shares in its offering — eight million more than it had expected — at $19 apiece, indicating strong demand from investors. ...

What is CG oncology IR?

More events are coming soon. CG Oncology Investor relations (IR) website contains information about our business for stockholders, potential investors, and financial analysts. ...

How much is CG oncology worth?

If the offering is priced at the top end of the indicated range, CG Oncology would be valued at $1.1 billion in the IPO. Morgan Stanley, Goldman Sachs, Cantor and LifeSci Capital are the underwriters. The company is seeking to list on the Nasdaq under the symbol "CGON". ...

Who is CG oncology?

CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. We see a world where urologic cancer patients can benefit from our innovative immunotherapies to live with dignity and have an enhanced quality of life. ...

Where can I learn more about CG oncology?

To learn more, please visit: www.cgoncology.com. CG Oncology cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. ...